Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Johnson & Johnson Innovation

Investor type Corporate Venture Capital


Unlock datapoints

Portfolio analytics



News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 68
Average round size
The average size of a deal this fund participated in
Portfolio companies 55
Rounds per year 1.39
Lead investments 16
Follow on index
How often the fund supports its portfolio startups at next rounds
Exits 11
Key employees 8

Areas of investment

  • Biotechnology
  • Health Care
  • Medical
  • Medical Device
  • Therapeutics

The main department of described VC is located in the New Brunswick. The company was established in North America in United States. Johnson & Johnson Innovation appeared to be a CVC structure as part of the corporation.

The top activity for fund was in 2016. The higher amount of exits for fund were in 2019. Opposing the other organizations, this Johnson & Johnson Innovation works on 16 percentage points less the average amount of lead investments. The fund is generally included in 7-12 deals every year. The average startup value when the investment from Johnson & Johnson Innovation is more than 1 billion dollars. The common things for fund are deals in the range of 10 - 50 millions dollars. Considering the real fund results, this VC is 6 percentage points more often commits exit comparing to other organizations.

The typical case for the fund is to invest in rounds with 5-6 participants. Despite the Johnson & Johnson Innovation, startups are often financed by Johnson & Johnson Development Corporation, Novartis Venture Fund, Sanderling Ventures. The meaningful sponsors for the fund in investment in the same round are Novartis Venture Fund, Pfizer Venture Investments, ARCH Venture Partners. In the next rounds fund is usually obtained by Innovate UK, W.L. Gore & Associates, Vertex Ventures HC.

The overall number of key employees were 8.

Among the most popular fund investment industries, there are Medical, Health Care. Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Among the most popular portfolio startups of the fund, we may highlight Carbon3D, Merus, Fusion Pharmaceuticals. The fund has exact preference in some founders of portfolio startups. If startup sums 5+ of the founder, the chance for it to be financed is low.

Read more

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Cara Care

Health Care
Health Diagnostics
Medical Device
$7M13 Jun 2022 Berlin, Berlin, Germany

Moon Surgical

Health Care
Medical Device
$31M07 Jun 2022 Paris, Ile-de-France, France

Enhanc3D Genomics

26 May 2022 Cambridge, Massachusetts, United States

Locus Biosciences

$35M18 May 2022 North Carolina, United States

IndyGeneUS AI

12 May 2022 Washington, District of Columbia, United States

Glyphic Biotechnologies

Life Science
$50K10 Nov 2021 San Francisco, California, United States

TRex Bio

$59M22 Jun 2021 South San Francisco, California, United States

On Target Laboratories

Life Science
$21M24 Mar 2021 Illinois, United States

Aro Biotherapeutics

$88M05 Jan 2021 Philadelphia, Pennsylvania, United States
Iterative Scopes Raises $30 Million Series A Financing to Advance AI-Driven Precision Medicine for Gastroenterology

– Iterative Scopes closed a $30m Series A financing.
– The round was led by new investor Obvious Ventures, with participation from Eli Lilly, Johnson & Johnson Innovation, the venture capital firms Breyer Capital and Seae Ventures, as well as a number of leaders in healthcare, including Lee Shapiro, Zach Weinberg and Nat Turner.
– The funds will be used to further develop the company’s core algorithmic innovations and to advance its growing life sciences businesses.
– The company is building a powerful set of proprietary artificial intelligence (AI)-driven computational tools to identify appropriate treatments and guide clinical trials for patients suffering from gastrointestinal diseases.

Ribon Therapeutics Secures $65 Million Financing

– Ribon Therapeutics announced the closing of a $65m financing.
– The financing was led by Deerfield Management and U.S. Venture Partners, with support from new investors Avego BioScience Capital, GV (formerly Google Ventures), Monashee Investment Management and Peregrine Ventures, along with existing investors AbbVie Ventures, Bristol Myers Squibb, Euclidean Capital, Johnson & Johnson Innovation, Novartis Venture Fund, Osage University Partners, Takeda Ventures and The Column Group.
– Ribon will use the proceeds to support the clinical development of its novel precision medicine candidates.


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Johnson & Johnson Innovation?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: